Showing results (141-150 of 258) with videos related to

Sort By:
Pageof 26
Human Pathology|March 19, 2010
The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancerAkihiko Kawahara, Koichi Azuma, Satoshi Hattori, et al.
Nuclear Medicine Communications|October 31, 2013
The difference in relationship between 18F-FDG uptake and clinicopathological factors on thyroid, esophageal, and lung cancersHayato Kaida, Akihiko Kawahara, Masanobu Hayakawa, et al.
Annals of Surgical Oncology|March 1, 2019
A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell CarcinomaTaichi Matsubara, Kazuki Takada, Koichi Azuma, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 9, 2019
Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort studyEiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, et al.
Annals of Surgical Oncology|March 1, 2019
Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma PatientsShinkichi Takamori, Kazuki Takada, Koichi Azuma, et al.
BMC Cancer|January 3, 2023
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trialSatoru Miura, Yasuhiro Koh, Koichi Azuma, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 22, 2019
Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysisEiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, et al.
Antiviral Research|November 7, 2016
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosisEiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 5, 2016
Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosisEiichi Ogawa, Norihiro Furusyo, Naoki Yamashita, et al.
World Journal of Hepatology|November 27, 2015
Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis CSatoshi Hiramine, Norihiro Furusyo, Eiichi Ogawa, et al.
Pageof 26